The government is moving quickly and trying to anticipate the spike in cases of the spread of the COVID-19 virus, one of which is by providing Telemedicine drug packages. This Telemedicine medicine package is provided for patients exposed to the COVID-19 virus, especially those who carry out independent isolation or have mild symptoms.

This is done to prevent the accumulation of patients in the hospital so that medical personnel can remain focused on treating patients with severe symptoms and other patients who need intensive care.

The Director General of Pharmaceuticals and Medical Devices Lucia Rizka Andalucia, accompanied by the Director of Public Drug and Health Supplies Management and the Director of Pharmaceutical Services, inspected the Kimia Farma Pharmacy in the Bendungan Hilir-Central Jakarta area regarding the availability of Telemedicine Drug Packages for COVID-19 patients on Thursday, February 3, 2022. There are several problems and follow-up actions agreed upon during the inspection, which are expected to improve and become an improvement in the quality of service of this Telemedicine Package. Kimia Farma Bendungan Hilir will be a test site for the implementation of Telemedicine which will later be adopted by other regions.

Given that the community exposed to COVID-19 is dominated by patients who carry out independent isolation, this activity is carried out to ensure the readiness and availability of Telemedicine package drugs for COVID-19 patients. So that the availability of drugs for self-isolating patients can be guaranteed.